Eisai to present new data for lenvatinib in hepatocellular carcinoma and renal cell carcinoma at ESMO 2017 Congress (2)

About Eisai Co., Ltd.   Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realise our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries. 

For more information about Eisai Co., Ltd., please visit www.eisai.com [http://www.eisai.com ].

References   1. Vogel A, et al. Health-related quality of Life (HRQOL) and disease symptoms in patients with unresectable hepatocellular carcinoma (HCC) treated with lenvatinib (LEN) or sorafenib (SOR). European Society for Medical Oncology (ESMO) 2017 Congress; Abstract No. 3209.   2. Cheng A, et al. Phase 3 trial of lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma (uHCC). American Society for Clinical Oncology annual meeting 2017; Abstract No. 4001.  3. Nexavar Summary of Product Characteristics 2007. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product... /WC500027704.pdf [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... ] . Last accessed August 2017.   4. European Medicines Agency. Nexavar Assessment History. Available at: www.ema.europa.eu/ema/index.jsp?curl=pag... _000929.jsp&mid=WC0b01ac058001d124 [http://www.ema.europa.eu/ema/index.jsp?c... ] . Last accessed August 2017.   5. Lee CH, et al. A Phase 1b/2 Trial of Lenvatinib Plus Pembrolizumab in Patients With Renal Cell Carcinoma. European Society for Medical Oncology (ESMO) 2017 Congress; Abstract No. 3765.  6. Tremblay G et al. Network Meta-Analysis (NMA) of Treatments for Unresectable Hepatocellular Carcinoma (uHCC). European Society for Medical Oncology (ESMO) 2017 Congress; Abstract No. 3909.  7. Ikeda M et al. A Phase 2 Study of Lenvatinib Monotherapy as Second-line Treatment in Unresectable Biliary Tract Cancer: Primary Analysis Results. European Society for Medical Oncology (ESMO) 2017 Congress; Abstract No. 2304.  8. Finn R et al. Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC). European Society for Medical Oncology (ESMO) 2017 Congress; Abstract No. 3193.  9. Garib S et al. Comparing ITC Results from Lenvatinib Plus Everolimus for Second-line Treatment of Advanced/Metastatic Renal Cell Carcinoma: Crossover Versus No Crossover. European Society for Medical Oncology (ESMO) 2017 Congress; Abstract No. 3632.  10. Tahara M et al. Impact of Duration of Dose Interruption on the Efficacy of Lenvatinib (LEN) in a Phase 3 Study in Patients (pts) With Radioiodine Refractory Differentiated Thyroid Cancer (RR-DTC). European Society for Medical Oncology (ESMO) 2017 Congress; Abstract No. 3074.   11. ClinicalTrials.gov. (2007) A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma. E7080-G000-304. Available at: clinicaltrials.gov/ct2/show/study/NCT01761266?term=E7080-G000-304&cond=Hepatocellular+Carc inoma&rank=1#locn. Last accessed August 2017.   12. Matsui J, et al. (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 122:664-671.  13. Okamoto K, et al. (2014) Distinct Binding Mode of Multikinase Inhibitor Lenvatinib Revealed by Biochemical Characterization. ACS Medicinal Chemistry Letter.  14. Lenvima Summary of Product Characteristics 2017. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product... /WC500188674.pdf [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... ] . Last accessed August 2017.   15. Kisplyx Summary of Product Characteristics 2017. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product... /WC500216237.pdf [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... ] . Last accessed August 2017.     16. Halaven Summary of Product Characteristics 2016. Available at: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product... /WC500105112.pdf [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_... ] . Last accessed August 2017.

Lenvatinib-EU0105    August 2017 

CONTACT: Media Enquiries: Eisai Europe Ltd, Helena Symeou, +44 7507 309895, Helena_Symeou@eisai.net Tonic Life Communications, Callum Haire, +447590 976 499, Callum.Haire@toniclc.com